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Abstract
Estrogen and estrogen-related compounds have been shown to have very potent cytoprotective properties in a wide range
of disease models, including an in vitro model of Friedreich’s ataxia (FRDA). This study describes a potential estrogen
receptor (ER)-independent mechanism by which estrogens act to protect human FRDA skin fibroblasts from a BSO-induced
oxidative insult resulting from inhibition of de novo glutathione (GSH) synthesis. We demonstrate that phenolic estrogens,
independent of any known ER, are able to prevent lipid peroxidation and mitochondrial membrane potential (DYm)
collapse, maintain ATP at near control levels, increase oxidative phosphorylation and maintain activity of aconitase.
Estrogens did not, however, prevent BSO from depleting GSH or induce an increased expression level of GSH. The
cytoprotective effects of estrogen appear to be due to a direct overall reduction in oxidative damage to the mitochondria,
enabling the FRDA fibroblast mitochondria to generate sufficient ATP for energy requirements and better survive oxidative
stress. These data support the hypothesis that phenol ring containing estrogens are possible candidate drugs for the delay
and/or prevention of FRDA symptoms.
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Introduction
First reported in 1863 by Nikolaus Friedreich [1,2,3],
Friedreich’s Ataxia (FRDA) has an incidence of 1:50,000–
1:20,000 and a carrier rate of 1:120–1:60 in the Caucasian
population of the United States, making it the most prevalent form
of hereditary ataxia [4,5,6,7]. This disorder is inherited in an
autosomal recessive manner caused by a GAA repeat expansion in
the first intron of the FXN gene on chromosome 9q13-21 [8,9],
causing a self-associating complex of sticky DNA to form,
hindering transcription [10] and significantly reducing the
expression of Frataxin [11,12,13,14]. The number of GAA repeats
on the smaller allele is inversely proportional to the intracellular
levels of Frataxin [15] and positively correlated to the severity of
patient symptoms [16,17]. Although the exact role of Frataxin is
currently unclear, its loss has two direct effects in several reported
tissue types: impaired formation of iron-sulfur (Fe-S) clusters and a
rise in intracellular reactive oxygen species (ROS) [6,7,14,18]. The
decrease in Fe-S containing proteins, such as heme, electron
transport chain (ETC) complexes I–III and the Kreb’s cycle
protein aconitase severely impairs cellular respiration
[14,19,20,21], which is further complicated by simultaneous
oxidative damage to these mitochondrial proteins
[13,18,21,22,23]. These events all culminate in an inability of
the mitochondria to fulfill the cell’s energy requirements resulting
in cell death [14], a mechanism of death common to many
neurodegenerative diseases (for review see Refs. [24,25]).
First established more than a decade ago [26,27], the neuro-
and cytoprotective effects of 17b-Estradiol (E2) are well known.
However the exact mechanisms remain elusive [24]. There are
now numerous reports showing that estrogen and estrogen-like
compounds are effective in protecting against a wide variety of
insults in numerous different cell types [28], including human
Friedreich’s ataxia skin fibroblasts [29]. Much current research
focuses on the mitochondrial mechanisms of estrogen neuropro-
tection [30]. It is known that ERa and ERb localize to the
mitochondria in many different cell types, including cerebrovas-
cular cells, primary neurons, cardiomyocytes and hippocampal cell
lines [31,32]. E2 upregulates expression of genes necessary for
oxidative phosphorylation encoded in both nuclear and mito-
chondrial DNA, elevating levels of these complexes and enhancing
aerobic ATP production [31]. E2 has been shown to provide
neuroprotection through the modulation of calcium flux in the cell
and calcium sequestration by the mitochondria in primary
hippocampal cells [33,34] and by increasing the expression of
the anti-apoptotic protein, Bcl-2 [33]. Estrogens have also been
shown to act on pro-survival pathways including ERK, CREB and
MAPK [35], and to have direct and indirect antioxidant effects
[24,29,30].
In a previous study, we showed that several estrogen-like
compounds are extremely potent and efficacious cytoprotectants of
human FRDA fibroblasts against L-buthionine (S,R)-sulfoximine
(BSO)-induced oxidative stress independent of any known estrogen
receptor (ER) [29]. This effect appears to be dependent on the
presence of at least one phenol ring in the molecular structure of
the compound and is at least in part due to antioxidant properties
and the attenuation of reactive oxygen species [29], a strategy
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[6,14,36,37,38]. However, as in other cell and animal disease
models, the precise mechanism of estrogen action in Friedreich’s
ataxia is not yet fully understood.
In this study, we investigate the mechanism of estrogen action in
human FRDA skin fibroblasts. Using BSO to induce oxidative
stress, we show that all phenolic estrogen-like compounds tested
are able to attenuate ROS production [29], prevent lipid
peroxidation and maintain mitochondrial function. This occurs
without the prevention of BSO-induced reduction of glutathione
(GSH). These effects are also independent of any known ER.
These data presented here indicate that estrogens effectively
prevent pro-oxidant stress in the mitochondria [6,36,37] by
preventing the excess ROS associated with FRDA from damaging
mitochondrial enzymes and inducing cell death.
Methods
Cell Culture
Fibroblasts from a 30 year old FRDA patient, obtained from
Coriell Institute (Camden, NJ, USA) were maintained in
Dulbecco’s Modified Eagle Medium (DMEM; ThermoScientific,
Waltham, MA, USA) with 10% charcoal-stripped fetal bovine
serum (FBS; ThermoScientific), 1% GlutaMAX (ThermoScienti-
fic) and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA,
USA) at 37uC, 5% CO2 and 90% humidity. Before vehicle or
BSO treatment, FRDA fibroblast media was changed to phenol
red- and sodium pyruvate-free DMEM (ThermoScientific) con-
taining 1% penicillin-streptomycin. All experiments were con-
ducted with FRDA cells from passage 14–21.
Chemicals & Reagents
17b-Estradiol (E2) was obtained from Steraloids, Inc. (Newport,
RI, USA). L-buthionine (S,R)-sulfoximine (BSO) was acquired
from Sigma-Aldrich (St Louis, MO, USA). ICI 182,780, 4,49,49-(4-
Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) and diarylpro-
pionitrile (DPN) were purchased from Tocris Bioscience (Ellisville,
MO, USA). ZYC-26 and ZYC-23 were synthesized in the Covey
laboratory [39]. Structures for these steroids were drawn using
ChemDraw software (CambridgeSoft, Cambridge, MA), and are
provided in Fig. 1.
Steroid Treatment
FRDA fibroblasts were plated in 24- or 96-well plates at a
density of 3,000–35,000 cells per well in DMEM with 10% FBS,
1% GlutaMAX and 1% penicillin-streptomycin. After 24 hours
the growth media was removed and replaced with the phenol red-
and sodium pyruvate-free DMEM. The cells were then treated for
12–48 hours, depending on the assay, with either dimethyl
sulfoxide vehicle control (DMSO; Sigma-Aldrich, St Louis, MO,
USA) or 1 mM BSO in the presence of 100 nM E2, DPN, PPT,
ZYC-26 or ZYC-23, concentrations of estrogen-like molecules
which have been shown to be neuroprotective in various cell lines
[40] and cytoprotective in this FRDA fibroblast line [29].
Calcein AM Cell Imaging
Cells were plated on a 96-well plate at a density of 5,000 cells
per well, then treated with vehicle or 1 mM BSO. After 24, 36 and
48 hours of BSO treatment, the media was removed, and 1 mg/
mL Calcein AM (CalBiochem, San Diego, CA, USA) in phosphate
buffer pH 7.2 (PBS; Fisher Scientific, Pittsburg, PA, USA) was
added to each well and the plate was incubated for 10 minutes at
37uC. The cells were then photographed using a Zeiss Axio
Observer Z1 inverted microscope (Carl Zeiss MicroImaging,
Thornwood, NY).
Lactate Dehydrogenase (LDH) Cell Viability Assay
After 48 hours of treatment 50 mL of media was removed from
each well of the 96-well plate and placed in a separate 96-well
plate. 100 mL of a solution consisting of 12 mL of 200 mM pH 8.2
Tris(hydroxymethyl)aminomethane hydrochloride (Sigma-Al-
drich, St Louis, MO, USA) with 50 mL lactic acid and 4.2 mg
iodonitrotetrazolium chloride (INT; Sigma-Aldrich, St Louis, MO,
USA), 1.1 mg phenazine methosulphate (PMS; Sigma-Aldrich, St
Louis, MO, USA) and 10.8 mg b-nicotinamide adenine dinucle-
otide hydrate (NAD; Sigma-Aldrich, St Louis, MO, USA) was
added to each well. The absorbance of the resulting reaction was
read with a Tecan Infinite M200 plate reader at 490 nm and
recorded once the reaction is linear for greater than 2 minutes.
Cell viability for each well (WellX) was determined by: 1002(100 *
(WellX - media)/(0.1%TritonX100-media)). Measurements were
then confirmed by visual inspection of the FRDA fibroblasts.
Western Blots
FRDA fibroblasts and 661W [41,42] photoreceptor cells were
grown in 10 cm plates until ,80% confluent. The cells were then
removed from the plates using rubber cell scrapers and sonicated
in RIPA lysis buffer. A Lowry assay was run to determine protein
concentration for normalization and 20 mg of protein was loaded
into each western blot well. ERa and ERb were detected using
ERa (H-184) rabbit polyclonal IgG antibody and ERb (H-150)
rabbit polyclonal IgG antibody, obtained from Santa Cruz
Biotechnology (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA). GAPDH (6C5) mouse monoclonal IgG antibody, also
obtained from Santa Cruz Biotechnology, was used as a control to
ensure equivalent loading of protein loaded into each well.
Lipid Peroxidation Assay
Cells were plated on 10 cm dishes and grown until ,80%
confluent. The cells were then treated with DMSO vehicle control
or BSO and 100 nM E2, PPT, DPN, ZYC-26 or ZYC-23 in
phenol red- and sodium pyruvate-free DMEM for 24 hours. At
the end of treatment, the FRDA fibroblasts were removed from
the plates using a rubber cell scraper and treated according to the
Cayman 8-Isoprostane EIA protocol (Cayman Chemical Compa-
ny, Ann Arbor, MI). The resulting absorbance was read on a
Tecan Infinite F200 plate reader (Tecan Systems, Inc., San Jose,
CA) at 340 nm.
Aconitase Assay
Cells were plated in 10 cm dishes and grown until ,80%
confluent. The cells were then treated with DMSO vehicle control
or BSO and 100 nM E2, PPT, DPN, ZYC-26 or ZYC-23 in
phenol red- and sodium pyruvate-free DMEM for 24 hours. At
the end of treatment, the FRDA fibroblasts were removed from
the plates using a rubber cell scraper and treated according to the
Cayman protocol. The resulting absorbance was read on a Tecan
Infinite F200 plate reader at 340 nm.
Mitochondrial Respiration Measurement
Human FRDA fibroblasts were plated in a 24-well Seahorse
XF-24 assay plate at 35,000 cells/well and grown in FBS-
containing DMEM media for 24 hours before being treated with
either BSO or DMSO vehicle control and steroids for another
24 hours in FBS- and Phenol-red-free DMEM media. On the day
of metabolic flux analysis, cells were changed to unbuffered
Estrogens Prevent Mitochondrial Damage
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glucose, 10 mM sodium pyruvate, 31 mM NaCl, 2 mM Gluta-
Max, pH 7.4) and incubated at 37uC in a non-CO2 incubator for
1 hr. All media was adjusted to pH 7.4 on the day of assay. Eight
baseline measurements of OCR and ECAR were taken before
sequential injection of mitochondrial inhibitors, oligomycin
(10 mM), FCCP (1 mM) and rotenone (5 mM). Four measurements
were taken after each addition of mitochondrial inhibitor before
injection of the next inhibitor. Oxygen consumption rate (OCR,
an indicator of oxidative phosphorylation) and extracellular
acidification rate (ECAR, an indicator of glycolysis) were
automatically calculated and recorded by the Seahorse XF-24
software (Seahorse Bioscience, North Billerica, MA, USA).
ATP Assay
Cells were plated on 10 cm dishes and grown until ,80%
confluent. The cells were then treated with DMSO vehicle control
or BSO and 100 nM E2, PPT, DPN, ZYC-26 or ZYC-23 in
phenol red- and sodium pyruvate-free DMEM for 24 hours. At
the end of treatment, the FRDA fibroblasts were removed from
the plates using a rubber cell scraper and treated according to the
Abcam protocol (Abcam Inc., Cambridge, MA), then were read
with an excitation of 535 nm and emission of 587 nm on a Tecan
Infinite F200 plate reader.
Mitochondiral Membrane Potential (DYm) Measurement
Cells were plated on 96-well plates at a density of 3,000 cells/
well. The cells were then treated with DMSO vehicle control or
BSO and 100 nM E2, PPT, DPN, ZYC-26 or ZYC-23 in phenol
red- and sodium pyruvate-free DMEM for 36 hours. A fluores-
cence resonance energy transfer (FRET) assay was used in this
study to measure mitochondrial membrane potential collapse. In
this assay, nonyl acridine orange (NAO; Enzo Life Sciences Inc.,
Plymouth Meeting, PA, USA) was used to stain cardiolipin in the
inner mitochondrial membrane. Tetramethylrhodamine, ethyl
ester, perchlorate (TMRE; AnaSpec Inc., Fremont, CA, USA) was
added simultaneously with NAO to the cell culture to quench the
NAO fluorescent signal, and incubated for 20 minutes at 37uCi n
the dark. As mitochondrial membrane potential collapsed at
36 hours after BSO treatment, TMRE was released from the
mitochondria, allowing the NAO fluorescent signature to be read
with an excitation of 495 nm and an emission of 519 nm with a
Tecan Infinite F200 plate reader [43,44,45].
Glutathione Assay
Cells were plated on 10 cm dishes and grown until ,80%
confluent. The cells were then treated with DMSO vehicle control
or BSO and 100 nM E2, PPT, DPN, ZYC-26 or ZYC-23 in
phenol red- and sodium pyruvate-free DMEM for 24 hours. At
the end of treatment, the FRDA fibroblasts were removed from
the plates using a rubber cell scraper and treated according to the
Cayman protocol. The resulting absorbance was read on a Tecan
Infinite F200 plate reader at 410 nm.
Data and Statistics
All data are displayed as mean 61 standard deviation. These
data were analyzed using ANOVA against an alpha level of 0.05.
All graphs were made using GraphPad Prism 5. For all groups,
n=8 wells and experiments were repeated three times to ensure
consistency.
Figure 1. Structures of compounds assessed for protection against BSO toxicity in FRDA fibroblasts.
doi:10.1371/journal.pone.0034600.g001
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All samples that are accepted into the Coriell Institute NIGMS
Human Genetic Cell Repository are collected with informed
consent according to the Guidelines from OHRP at the time of
collection, including the GM04078 line of human FRDA skin
fibroblasts used in this manuscript. In addition to the review of all
human subject requirements at the time of submission by a
committee of individuals trained in human subject protection from
research risk, the activities of the NIGMS Human Genetic
Repository are reviewed annually by the Institutional Review
Board of the Coriell Institute for Medical Research, represented
by Lorraine H. Toji, Ph.D., Vice Chair Coriell Institutional
Review Board. When samples are submitted, they are given a
Repository number and no links to the individual subject are
maintained.
Results
Human FRDA fibroblasts express small amounts of ERb,
but not ERa
To determine the presence or absence of ERa and ERb in
human FRDA fibroblasts, western blots were run showing the
intracellular presence of these proteins. Our western blots indicate
the absence of ERa in human FRDA fibroblasts and the presence
of very small amounts of ERb compared with 661W cells (Fig. 2).
These data agree with our previous pharmacological observations
utilizing ICI 182,780 and ZYC compounds, showing that estrogen
is likely not acting through any known ER to produce its effects on
cell viability and instead acts to block production of free radicals
[29].
Timeline of events in BSO-induced FRDA fibroblast cell
death
It was previously reported that after the application of 1 mM
BSO, large-scale cell death occurs at 48 hours (Fig. 3a) [29,36],
with a peak ROS level at 12 hours [29]. Here we have determined
a timeline of events beginning with BSO treatment that lead to
death in these FRDA fibroblasts. At 12 hours, ROS levels peak at
2–3 fold greater than control, which can be significantly
attenuated by co-treatment with estrogens. This is followed by a
rise in lipid peroxidation, impairment of aconitase activity,
disruption in mitochondrial respiration and reduced ATP content
at 24 hours (Figs. 4, 5, 6 and 7) and collapse of the mitochondrial
membrane potential (DYm) at 36 hours (Fig. 8), all of which can
be partially prevented with estrogen. Finally, at 48 hours there is
widespread cell death, which can be significantly reduced by
phenolic estrogens (Fig. 3b) [29].
Effects of steroids on cell viability in BSO-treated FRDA
fibroblasts
It has been previously reported that after the application of
1 mM BSO, large scale death occurs at 48 hours (Fig. 3a) [29,36],
with peak ROS levels at 12 hours [29]. To determine the effect of
100 nM E2, PPT, DPN, ZYC-26 and ZYC-23 on BSO-treated
fibroblasts, we measured cell viability via a LDH assay (Fig. 3b).
Figure 2. Western blot showing the presence of small amounts
of ERb and the absence of ERa in FRDA fibroblasts compared
with 661W photoreceptor cells.
doi:10.1371/journal.pone.0034600.g002
Figure 3. A.) Calcein AM imaging demonstrating cell viability between
vehicle control and BSO treatment groups at 24, 36 and 48 hours. Scale
bar=200 mm. B.) Effects of E2, PPT, DPN, ZYC-26 and ZYC-23 on cell
viability in BSO-treated FRDA fibroblasts. All steroid concentrations
were 100 nM, DMSO concentration was 0.1% and BSO concentration
was 1 mM. Depicted are mean 6 SD for n=8 per group. * indicated
p,0.05 versus BSO alone-treated cells.
doi:10.1371/journal.pone.0034600.g003
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to 4767%. All of the phenolic steroids provided significant
protection at 100 nM, with E2 at 9161%, PPT at 9466%, DPN
at 9464% and ZYC-26 at 8965%. ZYC-23 had no significant
effect at 100 nM with an average cell viability of 4965%, again
indicating that the phenolic ring is the crucial part of the estrogen
molecule in providing protection in this cell type (Fig. 1).
Effects of estrogens on lipid peroxidation measurements
To determine the extent of lipid peroxidation produced by
BSO-related oxidative stress, 8-isoprostane was measured at
24 hours, in DMSO control and BSO-treated cells in the presence
and absence of E2, PPT, DPN, ZYC-26 and ZYC-23 (Fig. 4).
BSO increased the level of lipid peroxidation by more than 1.5-
fold over DMSO control cells, as measured by intracellular 8-
isoprostane concentration at 24 hours. This increase in lipid
peroxidation was prevented by each of the phenolic estrogens, but
not ZYC-23, indicating that the antioxidant properties of the
phenolic rings of these compounds are able to prevent not only
ROS accumulation, but also the resulting oxidative damage to
intracellular molecules in these cells.
Effects of estrogens on aconitase activity
Aconitase, an enzyme in the Kreb’s cycle responsible for
conversion of citrate to isocitrate, is an iron-sulfur containing
protein extremely sensitive to reactive oxygen species and has been
shown to be significantly inhibited in human FRDA cardiomyo-
cytes, although not in other tissues [6]. Here, we show that in
human FRDA fibroblasts there was more than a 50% decrease in
aconitase activity in cells treated with 1 mM BSO, and this was
partially prevented with co-treatment of all tested phenolic
estrogens, but not ZYC-23 (Fig. 5). There was a trend toward
compounds with increased numbers of phenolic rings having an
increased protective effect in terms of aconitase activity levels. This
suggests that estrogens are preventing the loss of aconitase activity
by preventing ROS damage to this enzyme.
Effects of estrogens on mitochondrial respiration
To determine if BSO decreases the level of aerobic ATP
production, we assessed the oxygen consumption rate (OCR) with
a Seahorse XF-24 metabolic flux analysis (Fig. 6a). BSO-induced
oxidative stress significantly decreased both the basal respiratory
rate (Fig. 6b) and the maximal respiratory rate (Fig. 6c) suggesting
that at 24 hours of BSO treatment permanent damage had
already been inflicted on the mitochondria. Interestingly, in the
BSO-treated cells, the maximal respiratory rate
(45.461.0 pMoles/min) was significantly lower than the basal
respiratory rate in the DMSO vehicle control cells
(50.162.0 pMoles/min) (Fig. 6a). Both E2 and ZYC-26 were
able to partially offset the decreased respiratory capacity in both
basal and maximal states (Fig. 6a). These two estrogens are
statistically equivalent in terms of basal respiratory rate rescue,
however ZYC-26 appears to be less efficacious at preventing
mitochondrial impairment under the maximal state (Figs. 6b and
6c). In all measurements, ZYC-23 provided no significant increase
in OCR compared to BSO-alone treated cells. Extracellular
acidification rate (ECAR), a measure of anaerobic glycolysis was
not statistically altered in any of the four groups (data not shown).
Importantly, all of the differences noted in Figures 6a–6c can be
attributed solely to mitochondrial dysfunction in living FRDA
fibroblasts, as there was no significant cell death present at
24 hours (Fig. 3a). These data indicate that phenol ring containing
estrogens are able to partially prevent BSO-induced free radical
damage to the mitochondria, independent of any known ER,
while non-phenol ring containing estrogens are not.
Effects of estrogens on cellular ATP concentration
To determine the effect of phenolic estrogens on ATP
production, we evaluated each of these estrogen-like compounds
with an intracellular ATP concentration assay. Although ATP
production and concentration in FRDA fibroblasts is relatively low
under baseline conditions compared to other cell types such as
primary neurons, BSO significantly reduced the intracellular ATP
content by about 35% beyond this level, an effect that was partially
prevented by the phenolic estrogens E2, PPT, DPN and ZYC-26,
but not the non-phenolic ZYC-23 (Fig. 7).
Mitochondrial Membrane Potential (DYm) Collapse
To determine the effect of estrogens on mitochondrial
membrane potential collapse, an event following ROS-induced
mitochondrial damage and preceding cell death, we assessed each
of our phenolic and non-phenolic compounds with a FRET assay
at 36 hours after BSO treatment, a time point at which there was a
peak rise in NAO fluorescence in the BSO treated cells (data not
Figure 4. Effects of E2, PPT, DPN, ZYC-26 and ZYC-23 on
intracellular lipid peroxidation in BSO-treated FRDA fibro-
blasts. All steroid concentrations were 100 nM, DMSO concentration
was 0.1% and BSO concentration was 1 mM. Depicted are mean 6 SD
for n=8 per group. * indicated p,0.05 versus BSO alone-treated cells.
1.0 normalized 8-isoprostane control concentration=6.23 pg/mL.
doi:10.1371/journal.pone.0034600.g004
Figure 5. Effects of E2, PPT, DPN, ZYC-26 and ZYC-23 on the
activity of aconitase in BSO-treated FRDA fibroblasts. All steroid
concentrations were 100 nM, DMSO concentration was 0.1% and BSO
concentration was 1 mM. Depicted are mean 6 SD for n=8 per group.
* indicated p,0.05 versus BSO alone-treated cells.
doi:10.1371/journal.pone.0034600.g005
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there was a 4–5 fold increase in NAO fluorescence in BSO treated
cells compared with DMSO controls. This effect was prevented by
the addition of 100 nM of the phenolic estrogens E2, PPT, DPN
and ZYC-26, but not ZYC-23 (Fig. 8). These data indicate that
estrogen-like compounds are able to prevent oxidative-stress
induced collapse of DYm, an event indicating mitochondrial
function disruption that occurs prior to cell death (Fig. 3a), and
that this effect is dependent on the presence of a phenol ring in the
molecular structure.
Effects of estrogens on glutathione concentrations
To determine if estrogens were acting to prevent BSO-induced
declines in GSH, we assessed GSH concentrations in control cells
and those treated with BSO for 24 hours. BSO significantly
reduced the levels of GSH below baseline control, and none of the
estrogen-like compounds assayed had any effect on GSH
concentrations (data not shown). These data show that estrogens
are not acting simply to prevent BSO from depleting glutathione
or to induce glutathione synthesis in vitro.
Figure 6. Effects of E2 and ZYC-26 on mitochondrial function in
BSO-treated FRDA fibroblasts. A.) Oxygen consumption rate (OCR;
in pMoles/min) B.) Basal respiratory rate (in pMoles/min) C.) Maximal
respiratory rate (in pMoles/min) All steroid concentrations were 100 nM,
DMSO concentration was 0.1% and BSO concentration was 1 mM.
Depicted are mean 6 SD for n=8 per group. * indicated p,0.05 versus
BSO alone-treated cells.
doi:10.1371/journal.pone.0034600.g006
Figure 7. Effects of E2, PPT, DPN, ZYC-26 and ZYC-23 on the
intracellular ATP concentration inside of BSO-treated FRDA
fibroblasts. All steroid concentrations were 100 nM, DMSO concen-
tration was 0.1% and BSO concentration was 1 mM. Depicted are mean
6 SD for n=8 per group. * indicated p,0.05 versus BSO alone-treated
cells. 100% normalized ATP control concentration=501 pM.
doi:10.1371/journal.pone.0034600.g007
Figure 8. Effects of E2, PPT, DPN, ZYC-26 and ZYC-23 on the
collapse of mitochondrial membrane in BSO-treated FRDA
fibroblasts. All steroid concentrations were 100 nM, DMSO concen-
tration was 0.1% and BSO concentration was 1 mM. Depicted are mean
6 SD for n=8 per group. * indicated p,0.05 versus BSO alone-treated
cells.
doi:10.1371/journal.pone.0034600.g008
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We have previously reported that 17b-estradiol and other
estrogen-like compounds are able to significantly attenuate ROS
production and prevent cell death in a human Friedreich’s ataxia
skin fibroblast model [29]. While the exact mechanism of estrogen
neuroprotection is currently unclear, there is mounting evidence
that the protective effects of estrogen-related compounds may
occur in cells in a nongenomic manner, independent of estrogen
receptor activation and subsequent gene expression
[24,46,47,48,49]. The antioxidant properties of estrogens [50]
are due to the presence of a phenol at position 3 on the A-ring of
estrogens [49,51]. This phenol ring is responsible for attenuating
ROS created by the Fenton reaction in vitro, produced in this study
using BSO, by a cyclic phenol-quinol mechanism [51].
In the present study, human FDRA fibroblasts were obtained
from skin-punch biopsies of a 30-yr-old FRDA patient from
Coriell Cell Repositories, a widely accepted cell model for studying
FRDA [36,37,38,52]. These cells were homozygous for the FRDA
trinucleotide repeat with 541 repeats present on the first allele and
420 present on the second. BSO was used in this model to inhibit
de novo glutathione synthesis, depleting an important component of
these cells’ intrinsic defenses against ROS and allowing for the
accumulation of ROS produced by natural cell processes, resulting
in cell death [29]. The mechanism by which BSO inhibits
production of GSH and results in cell death is depicted in Figure 9.
Because they are lacking in Frataxin, FRDA fibroblasts are
extremely sensitive to BSO-induced oxidative stress compared
with normal fibroblasts [36], and thus are used as an in vitro model
of the long-term consequences of absent Frataxin. Frataxin has
been shown to be influential in the production of Fe-S cluster
containing proteins [19,53,54] and to prevent intracellular ROS
rise caused by the toxic effects of excess intracellular iron [18]. In
this model, the rise in ROS resulting from the lack of both
Frataxin and GSH impairs Fe-S cluster proteins and damages key
components of the mitochondria, reducing ATP production and
resulting in cell death (Fig. 9).
Here we show that phenolic ring containing estrogens are able
to prevent ROS-induced damage of intracellular lipids and
proteins, and are able to maintain mitochondrial function despite
severe oxidative stress. All of the phenolic compounds tested have
been previously shown to prevent an increase in intracellular ROS
[29], and they are further able to prevent subsequent damage
caused by these ROS. Figures 4 and 5 show that phenolic
estrogens prevent oxidative damage to cellular lipids and to the
Kreb’s cycle protein, aconitase. It has previously been established
that E2 is capable of increasing levels of aconitase in vitro and in
vivo, and it is thought that this effect is mediated by a reduction in
ROS-related damage to aconitase [55,56]. Our results indicate
that ZYC-26 is able to prevent loss of aconitase activity, while
ZYC-23 is not, which argues that E2 increases aconitase activity
levels by reducing ROS-mediated damage to this protein in this
cell type. Phenolic estrogens also prevent damage to the
mitochondria and disruption of their function, as seen by
maintenance of oxidative phosphorylation and oxygen consump-
tion rates (Fig. 6), maintenance of near normal ATP levels in cells
treated with phenolic estrogens (Fig. 7), and the prevention of
DYm collapse (Fig. 8). It has been previously shown that E2 is
capable of enhancing overall mitochondrial respiration with the
Seahorse assay [57]. In this study we show that mitochondrial
function is greatly impaired by BSO, and that the maximal OCR
seen in BSO-treated fibroblasts is less than the resting OCR in
DMSO control cells (Fig. 6a). The fact that the baseline resting
OCR is statistically lower in BSO-treated fibroblasts (Fig. 6b)
indicates that there is permanent damage to the mitochondria in
these cells at 24 hours after BSO treatment, prior to any cell death
(Fig. 3a) [29,36,37].This BSO-induced mitochondrial damage can
be prevented by either E2 or ZYC-26, but not ZYC-23 in both
resting and maximal respiratory states (Figs. 6b and 6c), indicating
that the cellular respiratory depression observed in BSO-treated
FRDA fibroblasts is due to oxidative damage to the mitochondria
and that phenolic estrogens are acting to prevent this oxidative
damage in an ER-independent manner. The Seahorse data
produced in these experiments corresponds to the decrease in
intracellular ATP concentration observed in BSO-treated cells
(Fig. 7).
Taken together with results published previously [29], these
observations demonstrate that an oxidative insult produces a large
increase in reactive oxygen species, leading to consequent lipid,
protein and organelle damage, mitochondrial membrane collapse
and cell death. Similar to studies in tissue samples from human
Figure 9. Proposed mechanism of 17b-Estradiol in BSO-treated FRDA fibroblasts.
doi:10.1371/journal.pone.0034600.g009
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significant damage to the mitochondria resulting in the inability of
the ATP producing components of the cell to meet energy
requirements, leading to large-scale cell death. This can be
prevented by the simultaneous application of phenolic estrogens,
which effectively reduces the extent of the oxidative insult of
individual cells and prevents organelle damage. These data
provide a potential mechanism for the protective properties of
phenolic estrogens in this system.
In addition, our data support the growing body of evidence that
estrogens can act to protect cells and tissues from damage inflicted
by neurodegenerative disease by nongenomic means
[25,47,48,49]. Since FRDA can be predicted and diagnosed very
early [58,59,60], there is a window of opportunity to begin
treatment in newborns, years before any of the devastating cardiac
or neurological symptoms begin to develop, a time period in which
non-feminizing estrogen-like compounds may prove to be very
efficacious. This study presents the first potential mechanism by
which estrogens may be acting to prevent cell death in FRDA and
illustrates that non-feminizing estrogens are an attractive class of
candidate drugs for the prevention and delay of FRDA symptoms.
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